Role of amyloid β1–42 and neuroimaging biomarkers in Alzheimer’s disease
2011; Future Medicine; Volume: 5; Issue: 4 Linguagem: Inglês
10.2217/bmm.11.50
ISSN1752-0371
Autores Tópico(s)Cholinesterase and Neurodegenerative Diseases
ResumoBiomarkers in MedicineVol. 5, No. 4 EditorialRole of amyloid β1–42 and neuroimaging biomarkers in Alzheimer's diseaseSimone Lista & Enzo EmanueleSimone Lista† Author for correspondenceCenter of Pharmaceutical Biotechnology, University of Rome 'Tor Vergata', Via della Ricerca Scientifica, 1, I-00133 Rome, Italy. & Enzo EmanueleLiving Research s.a.s, Via Monte Grappa, 13, I-27038 Robbio (PV), ItalyPublished Online:23 Aug 2011https://doi.org/10.2217/bmm.11.50AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: Alzheimer's diseaseamyloid β1–42amyloid plaquesbiomarkercerebrospinal fluidmild cognitive impairmentMRIBibliography1 Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement.4(5),316–323 (2008).Crossref, Medline, Google Scholar2 Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet368(9533),387–403 (2006).Crossref, Medline, CAS, Google Scholar3 Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science297(5580),353–356 (2002).Crossref, Medline, CAS, Google Scholar4 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology34(7),939–944 (1984).Crossref, Medline, CAS, Google Scholar5 Hampel H, Shen Y, Walsh DM et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp. Neurol.223(2),334–346 (2010).Crossref, Medline, CAS, Google Scholar6 Andreasen N, Zetterberg H. Amyloid-related biomarkers for Alzheimer's disease. Curr. Med. Chem.15(8),766–771 (2008).Crossref, Medline, CAS, Google Scholar7 Prvulovic D, Hampel H. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin. Chem. Lab. Med.49(3),367–374 (2011).Crossref, Medline, CAS, Google Scholar8 Reiman EM, Chen K, Liu X et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA106(16),6820–6825 (2009).Crossref, Medline, CAS, Google Scholar9 Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302(4),385–393 (2009).Crossref, Medline, CAS, Google Scholar10 Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement.4(1),38–48 (2008).Crossref, Medline, CAS, Google Scholar11 Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med.8,89 (2010).Crossref, Medline, Google Scholar12 Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology60(4),652–656 (2003).Crossref, Medline, CAS, Google Scholar13 Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol.59(3),512–519 (2006).Crossref, Medline, CAS, Google Scholar14 Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol.2(10),605–613 (2003).Crossref, Medline, CAS, Google Scholar15 Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res.5(4),1010–1016 (2006).Crossref, Medline, CAS, Google Scholar16 Albertini V, Bruno A, Paterlini A et al.: Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin. Appl.4(3),352–357 (2010).Crossref, Medline, CAS, Google Scholar17 Buerger K, Frisoni G, Uspenskaya O et al. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp. Gerontol.44(9),579–585 (2009).Crossref, Medline, CAS, Google Scholar18 Mueller SG, Weiner MW, Thal LJ et al. The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clin. N. Am.15(4),869–877, (2005).Crossref, Medline, Google Scholar19 Mitchell AJ, Monge-Argilés JA, Sánchez-Paya J. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? Pract. Neurol.10(4),202–207 (2010).Crossref, Medline, Google Scholar20 Hampel H, Wilcock G, Andrieu S et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. DOI: 10.1016/j.pneurobio.2010.11.005 (2010) (Epub ahead of print).Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByExploring the Potential of Neuroproteomics in Alzheimer's DiseaseCurrent Topics in Medicinal Chemistry, Vol. 20, No. 25Thalamic volume loss as an early sign of amnestic mild cognitive impairmentJournal of Clinical Neuroscience, Vol. 68The Alzheimer Precision Medicine InitiativeJournal of Alzheimer's Disease, Vol. 68, No. 1Current state of Alzheimer's fluid biomarkers28 November 2018 | Acta Neuropathologica, Vol. 136, No. 6Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and NeurophysiologyJournal of Alzheimer's Disease, Vol. 64, No. s1Alzheimer's disease biomarker‐guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ 1–42 , total‐tau, phosphorylated‐tau, NFL, neurogranin, and YKL‐409 January 2018 | Alzheimer's & Dementia, Vol. 14, No. 4Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and TrialsCerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional StudyJournal of Alzheimer's Disease, Vol. 59, No. 4The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's DiseaseJournal of Alzheimer's Disease, Vol. 56, No. 2Evolving Relevance of Neuroproteomics in Alzheimer's Disease16 May 2017Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive DeclineJournal of Alzheimer's Disease, Vol. 48, No. s1Biomarkers in Sporadic and Familial Alzheimer's DiseaseJournal of Alzheimer's Disease, Vol. 47, No. 2 Vol. 5, No. 4 Follow us on social media for the latest updates Metrics Downloaded 276 times History Published online 23 August 2011 Published in print August 2011 Information© Future Medicine LtdKeywordsAlzheimer's diseaseamyloid β1–42amyloid plaquesbiomarkercerebrospinal fluidmild cognitive impairmentMRIFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)